Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by kuatoliveson Jan 16, 2018 8:23pm

219 Views

Post# 27372989

RE:RE:RE:RE:RE:RE:RE:News

Remember, REOLYSIN is the inflammation agent, not the cancer killer itself. They have to go through a bunch of drug combinations to see what works best. Since there is yet no cure, success is measured in rates of life prolongation. That's just the way it is for now. What is of the utmost significance was the 'manageable saftey profiles'. Were this stuff beginning to prove toxic, you could have kissed your investment goodbye.

"Furthermore, on-treatment biopsies show reovirus infection in cancer cells and immune infiltrates demonstrating the viruses ability to create a pro-inflammatory phenotype in treated tumors."

It looks like it's working. They just need to find the right agent to work with it.

Bullboard Posts

Eminent acquires promising Nevada gold project